Nevertheless, the proportions of participants with advanced-stage CKD in large randomized clinical trials (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER] trial13 and Researching Cardiovascular Events With a Weekly Incretin in Diabetes [REWIND] trial14) examining the clinical effects of GLP-1 receptor agonists were small despite enrollment of these patients in the trials. The gene discussed is GLP1R; the disease is chronic kidney disease.